 Triplets of irinotecan, oxaliplatin and infusional 5-fluorouracilFUleucovorin LV are associated with high response rates and long survival as first-line treatment for metastatic colorectal cancer mCRC. The oral fluoropyrimidine, capecitabine, is better tolerated and shows better response rates than 5-FULV in metastatic colorectal cancer. A phase I dose-escalation study established dose limiting toxicity DLT, maximum tolerated dose MTD and recommended phase II doses RPIID of irinotecan, oxaliplatin and capecitabine. This phase I II study is to determine dose-limiting toxicities DLTs, maximum tolerated dose MTD, phase II recommended dose RD of IXO and bevacizumab combination and safety at the RD in an expanded cohort. 